Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Theravance Biopharma, Inc.TBPH · Entity 5037 | EVP, Gen. Counsel, Secretary | August 20, 2021 | August 24, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Theravance Biopharma, Inc.
Report date August 20, 2021 · Filed August 24, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 277,831 |
Reported balance
After 2021-08-20 transaction · row 1
1 source rowRow 1 · 2021-08-20 · Tax withholding · Disposed 4,307 · Balance 277,831 F1: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2021 Filed Aug 24, 2021 19:03 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,307 | $14.05 | $60,513.35 |
DisclosureSEC source: 0001179110-21-008402 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,831 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| May 20, 2021 Filed May 24, 2021 18:18 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,310 | $17.80 | $76,718.00 |
DisclosureSEC source: 0001179110-21-005850 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,138 F1 · balance_after: Includes 1,401 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 14, 2021. Read SEC document |
| February 20, 2021 Filed Feb 23, 2021 18:15 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 31,869 | $18.79 | $598,818.51 |
DisclosureSEC source: 0001179110-21-002174 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,047 Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 17:51 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001540 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,916 Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 18:22 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,807 | $17.21 | $82,728.47 |
DisclosureSEC source: 0001179110-20-011375 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,916 Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 18:34 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,804 | $18.22 | $87,528.88 |
DisclosureSEC source: 0001179110-20-009273 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,723 Read SEC document |
| May 20, 2020 Filed May 22, 2020 18:11 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,807 | $26.67 | $128,202.69 |
DisclosureSEC source: 0001179110-20-006532 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,527 F1 · balance_after: Includes 1,402 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:13 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 29,402 | $25.90 | $761,511.80 |
DisclosureSEC source: 0001179110-20-002154 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,932 Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 19:05 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 54,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001208 · edgar.xml · nonDerivative · entry 2 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,334 F1 · shares: On March 15, 2016, the reporting person was granted a performance stock award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On February 3, 2020, the performance conditions applicable to 54,000 shares were achieved and such shares will vest on February 20, 2021, subject to the reporting person's continued service. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 19:05 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001208 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,334 Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 18:25 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 3,567 | $17.60 | $62,779.20 |
DisclosureSEC source: 0001179110-19-012021 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,334 Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 18:06 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 3,084 | $21.51 | $66,336.84 |
DisclosureSEC source: 0001179110-19-009796 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,901 Read SEC document |
| May 20, 2019 Filed May 22, 2019 18:15 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 2,488 | $19.84 | $49,361.92 |
DisclosureSEC source: 0001179110-19-006534 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,985 F1 · balance_after: Includes 1,027 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2019. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 18:22 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 5,798 | $27.00 | $156,546.00 |
DisclosureSEC source: 0001179110-19-002429 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,446 Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 17:49 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 47,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001570 · edgar.xml · nonDerivative · entry 2 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,244 F1 · shares: On March 15, 2016, the reporting person was granted a performance stock award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On February 5, 2019, the performance conditions applicable to 47,250 shares were achieved and such shares will vest on February 20, 2020, subject to the reporting person's continued service. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 17:49 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001570 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,994 Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 17:46 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 7,006 | $24.79 | $173,678.74 |
DisclosureSEC source: 0001179110-18-013110 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,994 Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 18:24 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 7,119 | $27.71 | $197,281.73 |
DisclosureSEC source: 0001179110-18-011003 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,000 F1 · price: This transaction was executed in multiple trades at prices from $27.65 to $27.75. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 19:34 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 7,005 | $26.95 | $188,784.75 |
DisclosureSEC source: 0001179110-18-010822 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,119 Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 19:46 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 25,355 | $27.85 | $706,182.39 |
DisclosureSEC source: 0001179110-18-010467 · edgar.xml · nonDerivative · entry 3 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,124 F3 · price: This transaction was executed in multiple trades at prices from $27.63 to $28.18. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 19:46 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 4,127 | $28.03 | $115,686.00 |
DisclosureSEC source: 0001179110-18-010467 · edgar.xml · nonDerivative · entry 2 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,479 F2 · price: This transaction was executed in multiple trades at prices from $28.015 to $28.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 19:46 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 1,818 | $28.99 | $52,706.73 |
DisclosureSEC source: 0001179110-18-010467 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,606 F1 · price: This transaction was executed in multiple trades at prices from $28.60 to $29.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 08, 2018 Filed Jun 8, 2018 19:34 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 3,900 | $23.66 | $92,259.96 |
DisclosureSEC source: 0001179110-18-008316 · edgar.xml · nonDerivative · entry 2 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,424 F2 · price: This transaction was executed in multiple trades at prices from $23.50 to $24.21. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 19:34 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 10,140 | $24.09 | $244,267.53 |
DisclosureSEC source: 0001179110-18-008316 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,324 F1 · price: This transaction was executed in multiple trades at prices from $24.05 to $24.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 20, 2018 Filed May 22, 2018 19:02 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 21,812 | $24.31 | $530,249.72 |
DisclosureSEC source: 0001179110-18-007375 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,464 Read SEC document |
| May 14, 2018 Filed May 16, 2018 19:04 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 33,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006939 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,276 F1 · shares: On March 15, 2016, the reporting person was granted a performance stock award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On May 14, 2018, the performance conditions applicable to 33,750 shares were achieved and such shares will vest on May 20, 2018. F2 · balance_after: Includes 865 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2018. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 17:41 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 5,587 | $29.09 | $162,525.83 |
DisclosureSEC source: 0001179110-18-002612 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,661 Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 18:22 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002127 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,248 Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 16:40 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 7,079 | $28.58 | $202,317.82 |
DisclosureSEC source: 0001179110-17-014566 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,248 Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 18:53 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 14,670 | $30.77 | $451,350.42 |
DisclosureSEC source: 0001179110-17-012159 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,327 F1 · price: This transaction was executed in multiple trades at prices from $30.69 to $30.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 20, 2017 Filed Aug 22, 2017 18:30 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 7,079 | $27.40 | $193,964.60 |
DisclosureSEC source: 0001179110-17-011751 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,997 Read SEC document |
| May 20, 2017 Filed May 23, 2017 20:00 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 7,079 | $36.83 | $260,719.57 |
DisclosureSEC source: 0001179110-17-007881 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,076 F1 · balance_after: Includes 1,702 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2017. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 19:05 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 26,829 | $31.86 | $854,771.94 |
DisclosureSEC source: 0001179110-17-004176 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,453 F1 · price: This transaction was executed in multiple trades at prices from $31.86 to $31.91. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transactions set forth in footnotes (1) through (3) to this Form 4 were effected. Read SEC document |
| February 20, 2017 Filed Feb 22, 2017 19:07 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 12,440 | $33.78 | $420,223.20 |
DisclosureSEC source: 0001179110-17-002994 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,282 Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 19:09 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002002 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,722 Read SEC document |
| November 20, 2016 Filed Nov 22, 2016 18:04 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,008 | $31.96 | $128,095.68 |
DisclosureSEC source: 0001179110-16-031980 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,722 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.